These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26809940)

  • 41. Evaluation of bone mineral density in Iranian HIV/AIDS patients.
    Badie BM; Soori T; Kheirandish P; Izadyar S; SeyedAlinagh S; Foroughi M; Rostamian A; Mohraz M
    Acta Med Iran; 2011; 49(7):460-7. PubMed ID: 21960080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Measurement of bone mineral density is unnecessary for monitoring of bisphosphonate treatment].
    Nishida A; Ito M
    Clin Calcium; 2011 Jan; 21(1):120-3. PubMed ID: 21187605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence and predictors of low bone mineral density and fragility fractures among HIV-infected patients at one Italian center after universal DXA screening: sensitivity and specificity of current guidelines on bone mineral density management.
    Mazzotta E; Ursini T; Agostinone A; Di Nicola AD; Polilli E; Sozio F; Vadini F; Pieri A; Trave F; De Francesco V; Capasso L; Borderi M; Manzoli L; Viale P; Parruti G
    AIDS Patient Care STDS; 2015 Apr; 29(4):169-80. PubMed ID: 25692868
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment strategy of osteoporosis after the bisphosphonates discontinuation.].
    Soen S
    Clin Calcium; 2017; 27(2):273-280. PubMed ID: 28123130
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120).
    Rozenberg S; Lanoy E; Bentata M; Viard JP; Valantin MA; Missy P; Darasteanu I; Roux C; Kolta S; Costagliola D;
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):972-80. PubMed ID: 22353022
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV infection and osteoporosis: pathophysiology, diagnosis, and treatment options.
    Rothman MS; Bessesen MT
    Curr Osteoporos Rep; 2012 Dec; 10(4):270-7. PubMed ID: 23100110
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Musculoskeletal disorders in HIV-infected patients.National AIDS Plan (PNS) and the AIDS Study Group (GESIDA)].
    Grupo de Expertos del Plan Nacional sobre el Sida y Grupo de Estudio de Sida
    Enferm Infecc Microbiol Clin; 2011; 29(7):515-23. PubMed ID: 21474209
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Osteoporosis management in patients with breast cancer: EMAS position statement.
    Trémollieres FA; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; van der Schouw YT; Senturk LM; Simoncini T; Stevenson JC; Stute P; Rees M
    Maturitas; 2017 Jan; 95():65-71. PubMed ID: 27802892
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bisphosphonates for osteoporosis--where do we go from here?
    Whitaker M; Guo J; Kehoe T; Benson G
    N Engl J Med; 2012 May; 366(22):2048-51. PubMed ID: 22571168
    [No Abstract]   [Full Text] [Related]  

  • 50. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
    [No Abstract]   [Full Text] [Related]  

  • 51. [Absolute risk for fracture and WHO guideline. Pharmacological intervention to prevent osteoporotic fractures in the elderly].
    Hosoi T;
    Clin Calcium; 2007 Jul; 17(7):1098-104. PubMed ID: 17607078
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Minodronate for the treatment of osteoporosis.
    Kubo T; Shimose S; Matsuo T; Fujimori J; Ochi M
    Drugs Today (Barc); 2010 Jan; 46(1):33-7. PubMed ID: 20200694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study.
    Bonjoch A; Figueras M; Estany C; Perez-Alvarez N; Rosales J; del Rio L; di Gregorio S; Puig J; Gómez G; Clotet B; Negredo E;
    AIDS; 2010 Nov; 24(18):2827-33. PubMed ID: 21045635
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glucocorticoid-induced osteoporosis.
    Berris KK; Repp AL; Kleerekoper M
    Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):446-50. PubMed ID: 17982350
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.
    Rey D; Treger M; Sibilia J; Priester M; Bernard-Henry C; Cheneau C; Javier RM
    Infect Dis (Lond); 2015 Feb; 47(2):88-95. PubMed ID: 25426996
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Corticosteroids: no drug prevention of fractures needed.
    Prescrire Int; 2009 Aug; 18(102):175. PubMed ID: 19746563
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Good and the Bad About the 2017 American College of Physicians Osteoporosis Guidelines.
    Lagari V; Gavcovich T; Levis S
    Clin Ther; 2018 Jan; 40(1):168-176. PubMed ID: 29196083
    [TBL] [Abstract][Full Text] [Related]  

  • 58. People living with HIV and fracture risk.
    Premaor MO; Compston JE
    Osteoporos Int; 2020 Sep; 31(9):1633-1644. PubMed ID: 32206852
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adverse effects of antiretroviral therapy: focus on bone density.
    Viganò A; Mora S
    Expert Opin Drug Saf; 2004 May; 3(3):199-208. PubMed ID: 15155148
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HIV and Bone Complications: Understudied Populations and New Management Strategies.
    Yin MT; Brown TT
    Curr HIV/AIDS Rep; 2016 Dec; 13(6):349-358. PubMed ID: 27730445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.